By Deanna M. Petersen, CBO of AVROBIO, as part of the From The Trenches feature of LifeSciVC One of the most common questions I get asked is how I got into the business side of the biotech industry, and in

By Ankit Mahadevia, CEO of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC For anyone that’s part of a fast paced, growing organization, resilience is the key to thriving.  It supports our audacity, ability to tune

By Rene Russo, CEO of Xilio Therapeutics, as part of the From The Trenches features of LifeSciVC When your team’s priority is to execute a well-formed plan, then a “heads down” focus is critical. We all recognize this situation, using

By Aoife Brennan, CEO of Synlogic, as part of the From The Trenches feature of LifeSciVC. From the first time I heard the story of the American chestnut, I was fascinated. It is a story with threads from history, ecology,

By Sush Patel, CCO of Replimune as part of the From The Trenches feature of LifeSciVC. After close to 20 years at Genentech (GNE) shaping and directing marketing and commercialization efforts for novel oncology therapies, I finally took the plunge

By Jonathan Montagu, CEO and Co-founder of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC Today marks an important point in our journey to patients as HotSpot Therapeutics announces its $100MM Series C financing.  This infusion

We’ve now entered the 46th straight quarter of biotech IPO activity. New equity issuance for biotech in 2021 has broken records for the amount of capital raised, topping even the strong years of 2020 and 2014. Although the open and

We just held our first-ever, and hopefully only, virtual Atlas Venture Annual Meeting for our investors. Although science is winning in this pandemic, we’re clearly not back to normal yet so felt it prudent to shift to a virtual format.

By Deanna Petersen and Holly May, Chief Business Officer and Chief Commercial Officer, respectively, of AVROBIO, as part of the From The Trenches feature of LifeSciVC Moving from traditional drug development and commercialization to gene therapy development and commercialization can

By Ankit Mahadevia, CEO and founder of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC Recently, Spero announced the filing of its first ever New Drug Application, for our medicine tebipenem Hbr.  Interestingly, as we approached

By Josh Brumm, CEO of Dyne Therapeutics, as part of the From The Trenches feature of LifeSciVC One morning in early June I was reading my LinkedIn feed and saw something that caught my eye – a university was establishing

By Aoife Brennan, CEO of Synlogic Therapeutics, as part of the From The Trenches feature of LifeSciVC The COVID-19 pandemic has upended life as we know it. Given so much uncertainty, it is a normal human impulse to want some